TriangleNCT02213926 · OUTCOME
Overall Response Rate (ORR) of ACP-196 (Acalabrutinib) in Subjects With Previously Treated MCL.
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- From the date of the first dose until 30 days after the last dose of the study drug or start of a new anti-cancer treatment, whichever came first, assessed up to approximately 4 year and 10 months. 1 cycle =28 days
What was measured
The overall response rate (ORR) is defined as the proportion of subjects achieving either a partial remission (response) (PR) or complete response (CR) according to the Lugano Classification for NHL (Cheson 2014) as assessed by investigators, where SD stands for Stable Disease, PD for Progressive Disease and NE for Not Evaluable.
Analysis population: The analysis population included all treated subjects.
Groups in this outcome
ACP-196 (Acalabrutinib)
ACP-196 (acalabrutinib) 100 mg BID
| Group | Source count |
|---|---|
| ACP-196 (Acalabrutinib) | 124 |
Reported measurements
Source class 1
CR
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| ACP-196 (Acalabrutinib) | 59 | Not reported | Not reported | Not reported | Not reported |
PR
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| ACP-196 (Acalabrutinib) | 42 | Not reported | Not reported | Not reported | Not reported |
SD
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| ACP-196 (Acalabrutinib) | 10 | Not reported | Not reported | Not reported | Not reported |
PD
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| ACP-196 (Acalabrutinib) | 10 | Not reported | Not reported | Not reported | Not reported |
NE
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| ACP-196 (Acalabrutinib) | 3 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 59
- title
- CR
- measurements
- group Id
- OG000
- value
- 42
- title
- PR
- measurements
- group Id
- OG000
- value
- 10
- title
- SD
- measurements
- group Id
- OG000
- value
- 10
- title
- PD
- measurements
- group Id
- OG000
- value
- 3
- title
- NE
- denoms
- counts
- group Id
- OG000
- value
- 124
- units
- Participants
- description
- The overall response rate (ORR) is defined as the proportion of subjects achieving either a partial remission (response) (PR) or complete response (CR) according to the Lugano Classification for NHL (Cheson 2014) as assessed by investigators, where SD stands for Stable Disease, PD for Progressive Disease and NE for Not Evaluable.
- groups
- description
- ACP-196 (acalabrutinib) 100 mg BID
- id
- OG000
- title
- ACP-196 (Acalabrutinib)
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- The analysis population included all treated subjects.
- reporting Status
- POSTED
- time Frame
- From the date of the first dose until 30 days after the last dose of the study drug or start of a new anti-cancer treatment, whichever came first, assessed up to approximately 4 year and 10 months. 1 cycle =28 days
- title
- Overall Response Rate (ORR) of ACP-196 (Acalabrutinib) in Subjects With Previously Treated MCL.
- type
- PRIMARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice